NCT03704298 - Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

May 7, 2021

Study Completion Date

December 15, 2022

Conditions

Relapsed/Refractory Large B-cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Administered according to package insert

DRUG

Fludarabine

Administered according to package insert

BIOLOGICAL

Axicabtagene Ciloleucel

A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously

BIOLOGICAL

Utomilumab

Administered as an IV infusion

Trial Locations (5)

Columbia University Medical Center, New York

Moffitt Cancer Center, Tampa

UCLA Hematology/ Oncology, Santa Monica

Stanford Cancer Institute, Palo Alto

Dana-Farber Cancer Institute, Boston